Literature DB >> 19070399

Disseminated intravascular coagulation (DIC) and non-small cell lung cancer (NSCLC): report of a case and review of the literature.

E Voulgaris1, G Pentheroudakis, A Vassou, N Pavlidis.   

Abstract

The clinical manifestation of disseminated intravascular coagulation (DIC) as paraneoplastic phenomenon is common in patients with lung cancer (especially in those with non small cell lung cancer).Surprisingly, only few data have been published on the prevalence of this phenomenon. Herein we present the case of a patient with metastatic giant-cell carcinoma of the lung complicated by DIC leading the patient to death. We also review the literature regarding the incidence, the pathogenesis and the therapy of DIC in NSCLC. As more effective therapy for lung cancer becomes available and patients live longer, DIC can be expected to be encountered more frequently. Because of this fact clinicians should be alert to the occurrence of such clotting disorders and should be familiar with their diagnosis and management.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19070399     DOI: 10.1016/j.lungcan.2008.10.027

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  8 in total

1.  Recombinant human soluble thrombomodulin (thrombomodulin alfa) to treat disseminated intravascular coagulation in solid tumors: results of a one-arm prospective trial.

Authors:  Kazuo Tamura; Hidehiko Saito; Hidesaku Asakura; Kohji Okamoto; Jun Tagawa; Toru Hayakawa; Nobuo Aoki
Journal:  Int J Clin Oncol       Date:  2014-11-12       Impact factor: 3.402

2.  Contrast-enhanced ultrasound with a novel nanoparticle contrast agent for clinical diagnosis in patients with non-small cell lung cancer.

Authors:  Na Li; Lu Han; Hui Jing
Journal:  Exp Ther Med       Date:  2017-08-16       Impact factor: 2.447

3.  Effect of Thrombomodulin Alfa on Disseminated Intravascular Coagulation in Patients with Lung Cancer.

Authors:  Kentaro Nakano; Kumiya Sugiyama; Hideyuki Satoh; Hajime Arifuku; Takayoshi Fujimatsu; Naruo Yoshida; Hiroyoshi Watanabe; Shingo Tokita; Tomoshige Wakayama; Masamitsu Tatewaki; Ryosuke Souma; Hiroyuki Masuda; Kenya Koyama; Hirokuni Hirata; Yasutsugu Fukushima
Journal:  Intern Med       Date:  2017-07-15       Impact factor: 1.271

4.  Clinical features of patients with lung cancer accompanied by thromboembolism or disseminated intravascular coagulation.

Authors:  Nobuhiro Kanaji; Hitoshi Mizoguchi; Takuya Inoue; Akira Tadokoro; Naoki Watanabe; Tomoya Ishii; Yasunori Tojo; Masahiro Yamaguchi; Norimitsu Kadowaki
Journal:  Ther Clin Risk Manag       Date:  2018-08-01       Impact factor: 2.423

5.  Risk factors for disseminated intravascular coagulation in patients with lung cancer.

Authors:  Kentaro Nakano; Kumiya Sugiyama; Hideyuki Satoh; Sadaaki Shiromori; Kei Sugitate; Hajime Arifuku; Naruo Yoshida; Hiroyoshi Watanabe; Shingo Tokita; Tomoshige Wakayama; Masamitsu Tatewaki; Ryosuke Souma; Kenya Koyama; Hirokuni Hirata; Yasutsugu Fukushima
Journal:  Thorac Cancer       Date:  2018-05-31       Impact factor: 3.500

6.  Dramatic response of acute disseminated intravascular coagulation to erlotinib in a patient with lung adenocarcinoma with activating EGFR mutation.

Authors:  Jung Soo Kim; Jeong-Seon Ryu; Sang Hoon Jeon; Hyun-Jung Kim; Hae-Seong Nam; Jae Hwa Cho; Seung Min Kwak; Hong Lyeol Lee
Journal:  J Int Med Res       Date:  2017-07-21       Impact factor: 1.671

Review 7.  [Advances on mechanisms of coagulation with non-small cell lung cancer].

Authors:  Yanhua Li; Suju Wei
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2013-12

Review 8.  Disseminated intravascular coagulation complicating diagnosis of ROS1-mutant non-small cell lung cancer: A case report and literature review.

Authors:  Rachel Woodford; Michel Lu; Nadine Beydoun; Wendy Cooper; Qin Liu; Jodi Lynch; Lawrence Kasherman
Journal:  Thorac Cancer       Date:  2021-07-22       Impact factor: 3.500

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.